Arcus Capital Partners LLC Takes Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

Arcus Capital Partners LLC purchased a new position in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) during the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 1,453 shares of the medical research company's stock, valued at approximately $723,000.

Several other hedge funds have also made changes to their positions in TMO. Bernard Wealth Management Corp. acquired a new stake in Thermo Fisher Scientific in the 4th quarter valued at approximately $25,000. Ameriflex Group Inc. acquired a new position in shares of Thermo Fisher Scientific during the 4th quarter valued at $30,000. Cassady Schiller Wealth Management LLC lifted its holdings in shares of Thermo Fisher Scientific by 89.2% in the fourth quarter. Cassady Schiller Wealth Management LLC now owns 70 shares of the medical research company's stock valued at $36,000 after buying an additional 33 shares during the period. VSM Wealth Advisory LLC bought a new position in Thermo Fisher Scientific during the fourth quarter valued at about $36,000. Finally, Navigoe LLC bought a new stake in Thermo Fisher Scientific in the fourth quarter worth about $37,000. Institutional investors own 89.23% of the company's stock.

Thermo Fisher Scientific Stock Performance

NYSE TMO traded up $4.29 during trading on Friday, hitting $435.02. The company's stock had a trading volume of 2,511,384 shares, compared to its average volume of 1,999,630. The company has a quick ratio of 1.38, a current ratio of 1.77 and a debt-to-equity ratio of 0.64. The firm has a 50 day moving average price of $409.39 and a 200 day moving average price of $476.59. The firm has a market cap of $164.22 billion, a P/E ratio of 25.51, a price-to-earnings-growth ratio of 2.29 and a beta of 0.77. Thermo Fisher Scientific Inc. has a 52 week low of $385.46 and a 52 week high of $627.88.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its quarterly earnings data on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share for the quarter, topping the consensus estimate of $5.10 by $0.05. Thermo Fisher Scientific had a return on equity of 17.15% and a net margin of 15.19%. The company had revenue of $10.36 billion for the quarter, compared to analyst estimates of $10.23 billion. During the same quarter last year, the firm earned $5.11 EPS. Thermo Fisher Scientific's revenue for the quarter was up .2% compared to the same quarter last year. Equities research analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 15th. Shareholders of record on Monday, September 15th will be paid a dividend of $0.43 per share. The ex-dividend date is Monday, September 15th. This represents a $1.72 annualized dividend and a yield of 0.40%. Thermo Fisher Scientific's dividend payout ratio is 10.09%.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on TMO. The Goldman Sachs Group set a $610.00 price objective on shares of Thermo Fisher Scientific and gave the company a "buy" rating in a research report on Wednesday, April 23rd. Wall Street Zen upgraded shares of Thermo Fisher Scientific from a "hold" rating to a "buy" rating in a research report on Wednesday, May 21st. Evercore ISI cut their price objective on Thermo Fisher Scientific from $500.00 to $480.00 and set an "outperform" rating for the company in a research report on Tuesday. Wells Fargo & Company decreased their target price on Thermo Fisher Scientific from $580.00 to $570.00 and set an "overweight" rating on the stock in a report on Thursday, April 24th. Finally, Royal Bank Of Canada reduced their target price on Thermo Fisher Scientific from $651.00 to $637.00 and set an "outperform" rating for the company in a report on Thursday, April 24th. Four analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the stock. According to data from MarketBeat.com, Thermo Fisher Scientific has an average rating of "Moderate Buy" and a consensus price target of $600.30.

Insider Activity

In related news, EVP Gianluca Pettiti sold 300 shares of the firm's stock in a transaction on Monday, April 28th. The stock was sold at an average price of $429.93, for a total transaction of $128,979.00. Following the completion of the sale, the executive vice president directly owned 23,167 shares of the company's stock, valued at $9,960,188.31. This trade represents a 1.28% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Company insiders own 0.33% of the company's stock.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.